



Report #:

IF-824-QSA-TR006-BTL26480-12

Page 1 of 2



Title:

## Certificate of Analysis (CoA)

**Date:** 5/20/2026  
**Date Tested:** 5/18/2026  
**Customer:** Double Helix Labs  
**Testing material:** CJC-1295 Ipamorelin  
**Lot Number:** CJI012  
**BT Sample ID:** 005000040077253  
**Labeled Peptide**  
**Content/Potency:** 10 mg  
**Storage:** R.T.  
**Visual Description:** Small clear vial: white sample, silver holographic label, silver crimp, dark blue plastic cap.  
**Labeled as:** CJC-1295-IPA  
**Manufacturer:** HK  
**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test                                         | Method        | Specification                                                                  | Result                                                                                                   |
|----------------------------------------------|---------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| General Appearance                           | USP<br><630>  | white powder                                                                   | white powder                                                                                             |
| Mass                                         | USP<br><41>   | As recorded                                                                    | 67.8 mg                                                                                                  |
| FTIR Identification and Composition Analysis | USP<br><197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of CJC-1295 Ipamorelin with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP<br><621>  | Specifications: $\geq 98\%$                                                    | 99.8 %                                                                                                   |
| HPLC Potency Assay                           | USP<br><621>  | Specifications: 90 – 110% of 10 mg                                             | Ipamorelin 4.6 mg (46.1 %)<br>CJC-1295 8.0 mg (80.4 %)                                                   |
| Peptide-to-Excipients Ratio                  | USP<br><1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients)                | 12.6 : 55.2 mg (1:4.4)                                                                                   |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, AS  
Scientist-II  
BT Labs

Verna Zheng, AS  
Scientist-II  
BT Labs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407

Phone: (561) 941-4835

E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>


IF-824-QSA-TR006

Rev 1.0 January 2025


Title:

## Certificate of Analysis (CoA)

### FTIR ID and Composition Analysis: CJC-1295-IPA Lot CJI012



### HPLC Purity and Potency Assay @ 280 nm: CJC-1295-IPA Lot CJI012



#### CJC-1295 Ipamorelin Lot CJI012 @ 280 nm

| Peak #: | Retention Time (min) | Area (mAU*s) |
|---------|----------------------|--------------|
| 1       | 4.96                 | 1923.9       |
| 2       | 7.122                | 296.5        |